Press Releases

CPHI South East Asia  returns to Queen Sirikit National Convention Centre in the heart of Bangkok, as improving drug supply chain security is identified as the key macro trend driving growth in the region. In fact, a quickly improving reputation for supply chain standards is providing a boon for manufacturers regionally and creating a uniquely compelling business proposition when aligned with the highly competitive costs in the region. Emphasizing this surge in international pa

OSE Immunotherapeutics SA today announced that the trial’s Independent Drug Safety Monitoring Board provided a positive recommendation on the continuation until its completion of the Phase 2 clinical trial of IL-7 Receptor antagonist Lusvertikimab in ulcerative colitis. In parallel, the European Medicines Agency (EMA) provided a positive opinion on Orphan Drug Designation for Lusvertikimab for the treatment of Acute Lymphoblastic Leukemia (ALL). Nicolas Poirier, Chie

TiumBio Co., Ltd. a clinical-stage biopharmaceutical company focusing on discovering and development innovative therapeutics for patients with rare and incurable diseases, and Hansoh Pharmaceutical Group Co., Ltd. (SEHX: 3692), a leading biopharmaceutical company, announced that the China National Medical Products Administration (NMPA) approved Hansoh’s Investigational New Drug (IND) application for clinical study of HS-10518 (also known as TU2670), the management of moderate to severe

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, today announces it has taken a minority-share interest in Renovos Biologics (Renovos), an innovative biologics company born out of research into the properties of nanoclay at the University of Southampton, UK.  Michael Harris, CEO, Biocomposites will join Renovos Biologics Board of Directors.

Sensorion a pioneering clinical-stage biotechnology company dedicated to the development of innovative therapies to restore, treat and prevent hearing loss, today publishes a complementary analysis of its phase 2a clinical trial of proof of concept (POC) conducted with SENS-401 in the preservation of residual hearing in adult patients following cochlear implantation. The analysis of this preliminary data will be presented during the KOL webinar organized by the Company this Wednesday, July 5,

The global pharmaceutical excipients market size reached US$ 8.85 billion in 2021 and it is predicted to be worth around US$ 14.2 billion by 2030, registering a CAGR of 5.39% from 2022 to 2030. The demand for oral formulations of drugs has been rapidly increasing in recent years. This is primarily due to the convenience of consumption, especially for children. Oral dosage formats require more excipients during the manufacturing process compared to other drug forms. This trend is dri

CPHI & PMEC China will open a special roadshow to be hosted at the PWTC Expo in the city of Guangzhou. The new addition to this year’s CPHI calendar is in recognition of the sizable growth and international demand for manufacturers from the South China region. CPHI & PMEC China 2023 recently concluded with an exceptional turnout of visitors, setting a new attendance record. Notably, international attendees returned post-COVID, and professionals from various segments of

The newly launched PAS-X K.ME-IN partner program provides Werum PAS-X MES customers with an out-of-the-box interface for the use of biometric authentication technology. Together with partners this enables 50 percent faster identification times while ensuring only authorized personnel can access the Manufacturing Execution System (MES). With Integral Biometrics and obion (formerly i.p.a.s.-systeme), two strong partners have already joined the program. Körber’s Werum PAS-X

The global biopharmaceutical CMO and CRO market size is expected to touch USD 59.13 Billion by 2030, from USD 33.4 Billion in 2022, growing with a significant CAGR of 7.4% from 2022 to 2030. Read More: https://www.precedenceresearch.com/biopharmaceutical-cmo-and-cro-market The biopharmaceutical Contract Manufacturing Organizations (CMO) and Contract Research Organizations (CRO) play a crucial role in the biopharmaceutical industry. They are closely tied to and influenced by t

ENPICOM, an innovative bioinformatics software engineering company, has successfully secured further financial backing from its current investors BOP Capital, BOM Brabant Ventures, Nextgen Ventures, and Arches Capital. This underscores investor confidence in ENPICOM’s vision, unique technological capabilities, and exceptional track record in serving customers in the pharmaceutical and biotech industries. Recognizing the need for innovative data analysis solutions that provide